The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
Abstract
Thalidomide was a widely used drug in the late 1950s and early 1960s for the treatment of nausea in pregnant women. It became apparent in the 1960s that thalidomide treatment resulted in severe birth defects in thousands of children. Though the use of thalidomide was banned in most countries at that time, thalidomide proved to be a useful treatment for leprosy and later, multiple myeloma. In rural areas of the world that lack extensive medical surveillance initiatives, thalidomide treatment of pregnant women with leprosy has continued to cause malformations. Research on thalidomide mechanisms of action is leading to a better understanding of molecular targets. With an improved understanding of these molecular targets, safer drugs may be designed. The thalidomide tragedy marked a turning point in toxicity testing, as it prompted United States and international regulatory agencies to develop systematic toxicity testing protocols; the use of thalidomide as a tool in developmental biology led to important discoveries in the biochemical pathways of limb development. In celebration of the Society of Toxicology's 50th Anniversary, which coincides with the 50th anniversary of the withdrawal of thalidomide from the market, it is appropriate to revisit the lessons learned from the thalidomide tragedy of the 1960s.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Casarett and Doull's Toxicology: The Basic Science of Poisons
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-5-448_2 · Cited by 3,302
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
A short history of thalidomide embryopathy
Lenz, W. (1988) · Teratology · doi:10.1002/tera.1420380303 · Cited by 784
Thalidomide in the treatment of lepra reactions
Sheskin, J. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563303 · Cited by 533
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Fgf8 signalling from the AER is essential for normal limb development
Lewandoski, M., Sun, X., & Martin, G. R. (2000) · Nature Genetics · doi:10.1038/82609 · Cited by 451
Thalidomide: current and potential clinical applications
Calabrese, L., & Fleischer, A. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00408-8 · Cited by 324
Mechanism of action in thalidomide teratogenesis
Stephens, T. D., Bunde, C. J. W., & Fillmore, B. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00388-3 · Cited by 259
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
Therapontos, C., Erskine, L., Gardner, E. R., Figg, W. D., & Vargesson, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901505106 · Cited by 254
Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species
WELLS, P., BHULLER, Y., CHEN, C., JENG, W., KASAPINOVIC, S., KENNEDY, J., KIM, P., LAPOSA, R., MCCALLUM, G., & NICOL, C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.01.061 · Cited by 236
Thalidomide: A review of approved and investigational uses
Matthews, S. J., & McCoy, C. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80085-1 · Cited by 203
Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses
Miller, M. T., & Str�mland, K. (1999) · Teratology · doi:10.1002/(sici)1096-9926(199911)60:5<306::aid-tera11>3.0.co;2-y · Cited by 189
Thalidomide update: Regulatory aspects
Kelsey, F. O. (1988) · Teratology · doi:10.1002/tera.1420380305 · Cited by 122
Thalidomide induces limb deformities by perturbing the Bmp/Dkkl/Wnt signaling pathway
Knobloch, J., Shaughnessy, J. D., & Rüther, U. (2007) · The FASEB Journal · doi:10.1096/fj.06-7603com · Cited by 122
Hypothesis: Thalidomide embryopathy?proposed mechanism of action
Stephens, T. D., & Fillmore, B. J. (2000) · Teratology · doi:10.1002/(sici)1096-9926(200003)61:3<189::aid-tera6>3.0.co;2-w · Cited by 116
Proposed mechanisms of action in thalidomide embryopathy
Stephens, T. D. (1988) · Teratology · doi:10.1002/tera.1420380307 · Cited by 111
Johnson, D. C., Corthals, S. L., Walker, B. A., Ross, F. M., Gregory, W. M., Dickens, N. J., Lokhorst, H. M., Goldschmidt, H., Davies, F. E., Durie, B. G. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0792 · Cited by 104
Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects
Knobloch, J., & Rüther, U. (2008) · Cell Cycle · doi:10.4161/cc.7.9.5793 · Cited by 102
Hansen, J. M., & Harris, C. (2004) · Antioxidants and Redox Signaling · doi:10.1089/152308604771978291 · Cited by 98
Die sensible phase bei der thalidomid-embryopathie
Nowack, E. (1965) · Human Genetics · doi:10.1007/bf00338341 · Cited by 94
Hansen, J. M., Gong, S., Philbert, M. A., & Harris, C. (2002) · Developmental Dynamics · doi:10.1002/dvdy.10150 · Cited by 79
Knobloch, J., Schmitz, I., Götz, K., Schulze‐Osthoff, K., & Rüther, U. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00553-07 · Cited by 73
New cases of thalidomide embryopathy in Brazil
Schüler‐Faccini, L., Soares, R. C., de Sousa, A. C. M., et al. (2007) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.20384 · Cited by 72
Knobloch, J., Schmitz, I., Götz, K., Schulze‐Osthoff, K., & Rüther, U. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05712-11 · Cited by 72
Janer, G., Slob, W., Hakkert, B. C., Vermeire, T. G., & Piersma, A. H. (2007) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2007.11.007 · Cited by 61
Valproic acid-induced changes in gene expression during neurulation in a mouse model
Wlodarczyk, B. J., Craig, J. C., Bennett, G. D., Calvin, J. A., & Finnell, R. H. (1996) · Teratology · doi:10.1002/(sici)1096-9926(199612)54:6<273::aid-tera1>3.0.co;2-# · Cited by 61
Miller, M. T., Ventura, L., & Strömland, K. (2009) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.20609 · Cited by 56
Uhl, K., Cox, E. M., Rogan, R., et al. (2006) · Drug Safety · doi:10.2165/00002018-200629040-00003 · Cited by 54
Hansen, J. M., Carney, E. W., & Harris, C. (1999) · Reproductive Toxicology · doi:10.1016/s0890-6238(99)00053-2 · Cited by 48
Evaluation of the developmental toxicity of lenalidomide in rabbits
Christian, M. S., Laskin, O. L., Sharper, V. A., Hoberman, A. M., Stirling, D., & Latriano, L. (2007) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20115 · Cited by 46
Why I doubted that thalidomide was the cause of the epidemic of limb defects of 1959 to 1961
Warkany, J. (1988) · Teratology · doi:10.1002/tera.1420380304 · Cited by 45
Thalidomide Down-Regulates Transcript Levels of GC-Rich Promoter Genes in Multiple Myeloma
Drucker, L., Uziel, O., Tohami, T., Shapiro, H., Radnay, J., Yarkoni, S., Lahav, M., & Lishner, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.2.415 · Cited by 30
Cited by
Development of targeted protein degradation therapeutics
Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Alabi, S. B., & Crews, C. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100647 · Cited by 261
Drug Repurposing: An Effective Tool in Modern Drug Discovery
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020139 · Cited by 257
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 255
Metadata
- Authors
- Kim, J. H., & Scialli, A. R.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-19
- Volume
- 122
- Issue
- 1
- Pages
- 1-6
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2147890019
- Cited by
- 659
- References
- 33
- FWCI
- 15.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.